Money Genius Group
  • Investing
  • World News
  • Stock
  • Tech News
Investing

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

by May 27, 2025
May 27, 2025

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the ‘AGM’) will be webcast on May 28, 2025, at 4:30 p.m. EDT.

Cardiol Therapeutics’ 2025 AGM

When: May 28, 2025, at 4:30 p.m. EDT
Where: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161

Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com/investors/events-presentations/.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253470

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com
previous post
FPX Nickel and JOGMEC Initiate Exploration at the Expanded Klow Property in British Columbia
next post
Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases Via Direct Message

You may also like

Blue Sky Uranium: Argentina’s Emerging Uranium Resource Developer

May 27, 2025

Bitcoin Well Announces Nostr Integration; Including Bitcoin Purchases...

May 27, 2025

FPX Nickel and JOGMEC Initiate Exploration at the...

May 27, 2025

Crypto Market Review: Trump Media Planning US$3 Billion...

May 27, 2025

Crypto Market Review: Trump Media Planning US$3 Billion...

May 27, 2025

Concentrate Offtake Agreements Signed for Nueva Sabana Copper-Gold...

May 27, 2025

Concentrate Offtake Agreements Signed for Nueva Sabana Copper-Gold...

May 27, 2025

Exploration Target at Golden Crown to Focus on...

May 27, 2025

Exploration Target at Golden Crown to Focus on...

May 27, 2025

Completion of Airborne Survey Across NT Uranium Projects

May 27, 2025

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Learning Painful Lessons is the Start to Building a Successful Trading or Investing Strategy

      May 26, 2025
    • Week Ahead: NIFTY Stays In Technically Challanging Situation; Sector Rotation Shows Likely Change In Leadership

      May 25, 2025
    • My Durable Advantage as an Investor is My Experience: Here are Seven Examples

      May 24, 2025
    • 3 Stocks to Watch While Everyone’s Staring at NVIDIA

      May 24, 2025
    • Automate Your Scans with Ease! Sample Scan Library + Scheduled Scans Walkthrough

      May 24, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 moneygeniusgroup.com | All Rights Reserved

    Money Genius Group
    • Investing
    • World News
    • Stock
    • Tech News